Wednesday, July 8, 2026

pharma · Melanoma · Multiple Myeloma · RNA

Atrium Therapeutics

Atrium Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker RNA. Primary therapeutic focus areas include Melanoma, Multiple Myeloma, Germ Cell Tumor, Renal Carcinoma, Acut

10578 Science Center Dr, Suite 125, San Diego, California 92121, US HQ
2026 Founded
46 Employees
Public company Type
RNA · NYSE Ticker
Company details
Status
Public
HQ
10578 Science Center Dr, Suite 125, San Diego, California 92121, US
Founded
2026
Employees
46
Programs
31
Drugs
33
Patents
37
Clinical program

Metformin Hydrochloride ER

Phase 2 · small molecule · Sarcoma Metastatic

Metformin Hydrochloride ER for Sarcoma Metastatic is a Phase 2 program (small_molecule) at Atrium Therapeutics with 1 ClinicalTrials.gov record(s).

← All Atrium Therapeutics projects Phase 2 small molecule active

Internal code IRB00138078

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Atrium Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Sarcoma Metastatic
Status
active
Trials
1